Non-Alcoholic Steatohepatitis Treatment Market Outlook:
Non-Alcoholic Steatohepatitis Treatment Market size was valued at USD 9.21 billion in 2025 and is likely to cross USD 96.64 billion by 2035, registering more than 26.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-alcoholic steatohepatitis treatment is assessed at USD 11.41 billion.
There is a widespread presence of NASH comorbidities such as obesity, nonalcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), hypertension, high cholesterol, and metabolic syndrome. For instance, in 2022, the worldwide incidence of NAFLD was 47 per 1,000, and prevalence among adults was 32% (NLM). On the other hand, over 890 million people in the world were identified as obese in 2022 (WHO). Another estimation from the Institute of Health Metrics and Evaluation revealed that the diabetic population around the globe was 529 million in 2023, and 96 % of them had T2D. The figure is further projected to reach 1.3 billion by 2050. This demography represents a surge in demand and a large consumer base in the market.
According to a study published by NLM in July 2020, the annual direct medical expenses per patient were USD 1,613 in the U.S. and ranged between USD 402.2 and USD 1321.3 in Europe. This signifies a notable financial exhaustion for patients, making it hard for them to afford advanced solutions from the market. Thus, dedicated organizations in this field are continuously trying to find a cost-effective pathway to mitigate this economic hurdle. On this note, in April 2023, the Institute for Clinical and Economic Review suggested annual payers’ pricing of USD 39,600.0-50,100.0 and USD 32,600.0-40,400.0 for resmetirom and obeticholic acid to meet the cost-effectiveness threshold in treating liver fibrosis.
